

EuroSpA presentations at EULAR 2019			
Abstract 1.3	DOES DRUG EFFECTIVENESS OF 2 ND AND 3 RD TNF INHIBITORS IN PATIENTS WITH PSORIATIC ARTHRITIS DEPEND ON THE REASON FOR WITHDRAWAL FROM THE PREVIOUS TREATMENT? – RESULTS FROM THE EUROSPA RESEARCH COLLABORATION	POSTER	SAT0614
Abstract 1.2	TREATMENT RESPONSE AND DRUG RETENTION RATES IN 23,956 BIOLOGIC-NAÏVE PATIENTS WITH AXIAL SPONDYLOARTHRITIS INITIATING TNFI TREATMENT – ROUTINE CARE DATA FROM 12 REGISTRIES IN THE EUROSPA COLLABORATION	POSTER	SAT0625
Abstract 1.4	DOES DRUG EFFECTIVENESS OF 2 ND AND 3 RD TNF INHIBITORS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS DEPEND ON THE REASON FROM WITHDRAWAL FROM THE PREVIOUS TREATMENT? – RESULTS FROM THE EUROSPA RESEARCH COLLABORATION	GUIDED POSTER TOUR	FR0378
Abstract 1.1	DRUG RETENTION AND REMISSION RATES IN 14,261 BIOLOGIC-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS STARTING TNF INHIBITOR TREATMENT IN ROUTINE CARE – RESULTS FROM 12 REGISTRIES IN THE EUROSPA RESEARCH COLLABORATION	ABSTRACT BOOK	AB0752
Abstract 5.1	REMISSION AND DRUG RETENTION RATES OF SECUKINUMAB IN 1549 PATIENTS WITH PSORIATIC ARTHRITIS TREATED IN ROUTINE CARE – POOLED DATA FROM THE OBSERVATIONAL EUROSPA RESEARCH COLLABORATION NETWORK	POSTER	SAT0391
Abstract 2.3	DOES DISCORDANCE BETWEEN BASELINE PATIENT'S AND EVALUATOR'S GLOBAL ASSESSMENT OF DISEASE ACTIVITY IMPACT RETENTION AND REMISSION RATES OF TNF INHIBITORS IN PATIENTS WITH PSORIATIC ARTHRITIS? DATA FROM THE EUROSPA RESEARCH COLLABORATION	POSTER	FR0453
Abstract 5.2	POOLED 6-MONTH TREATMENT OUTCOMES AND DRUG RETENTION RATES IN 1556 PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH SECUKINUMAB IN ROUTINE CLINICAL PRACTICE IN 12 EUROPEAN COUNTRIES IN THE EUROSPA RESEARCH COLLABORATION	POSTER	FR0404
Abstract 2.4	HIGH BASELINE PATIENT'S COMPARED WITH EVALUATOR'S GLOBAL ASSESSMENT IS ASSOCIATED WITH LOWER RETENTION AND REMISSION RATES OF FIRST TNF INHIBITOR IN AXSPA PATIENTS - DATA FROM THE EUROSPA COLLABORATION	POSTER	FR0403